Novartis AG ADR (NVS)vsRoyalty Pharma Plc (RPRX)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
RPRX
Royalty Pharma Plc
$58.61
-0.24%
HEALTHCARE · Cap: $36.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2136% more annual revenue ($56.69B vs $2.54B). RPRX leads profitability with a 32.0% profit margin vs 22.5%. RPRX appears more attractively valued with a PEG of 1.49. RPRX earns a higher WallStSmart Score of 57/100 (C).
NVS
Buy51
out of 100
Grade: C-
RPRX
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
-64.9%
Fair Value
$36.75
Current Price
$58.61
$21.86 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Weak financial health signals
Earnings declined 46.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Debt/Equity, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while RPRX is a growth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
RPRX is growing revenue faster at 16.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (57/100 vs 51/100), backed by strong 32.0% margins and 16.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?